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there are established agencies that evaluate new pharmaceuticals to inform health care 
policy decisions (e.g., the HAS in France and NICE in the UK). This analysis will 
consider the strengths and weaknesses of European health technology bodies (HTA) 
and provide insight for the implementation of CER and how lessons learned from the 
UK and France might help improve efﬁciency and outcomes in oncology in the US. 
METHODS: Secondary research will be used to review how HTA bodies evaluate 
oncologics and assess their impact on market access. These countries were selected as 
they represent the extremes of HTA assessment in Europe. Findings from this research 
will then be contrasted against current market access in the US. RESULTS: While 
France evaluates new products on innovation and clinical value the UK largely bases 
market access decisions on cost-effectiveness. Consequently, many new oncology 
agents available in France have been denied funding in the UK. Meanwhile, insured 
Americans have relatively open access. CONCLUSIONS: Cancer remains the second 
leading cause of death in the US and is a growing health care burden. Therefore better 
informed policy decisions on the efﬁcient use of clinical services for oncology are 
critical. This analysis suggests that there is potential for the US to optimize on the 
European experiences when considering the adoption of a CER tool for oncology 
drugs management. Speciﬁcally, if the US does adopt a formal CER entity, it may wish 
to avoid using NICE-like economic-based outcomes to change clinical practice, but 
and aim to play an advisory role to facilitate better informed strategic decisions 
(HAS-like).
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ONCOLOGY DRUG REVIEW
Ciapanna CC1, Yunger S1, Shum D1, Milliken D1, Longo CJ2, Aissa F1
1Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2McMaster University, Hamilton, 
ON, Canada
OBJECTIVES: In Canada, the interim Joint Oncology Drug Review (JODR) conducts 
health technology assessments for all oncology products and provides funding recom-
mendations to participating provinces. Summaries of these recommendations are 
publically available, however investigation of the potential factors that inﬂuence 
these decisions has not been conducted. Furthermore, the acceptable incremental 
cost-effectiveness ratio (ICER) used by the JODR has not been published. This 
analysis was conducted to assess the differences in the average ICER between the 
JODR’s positive and negative recommendations and determine the relative inﬂuence 
of cost-effectiveness evidence on decision-making. METHODS: A literature search 
for pharmacoeconomic data was conducted for all 24 drugs with cancer indications 
reviewed by the JODR and made publicly available between March 2007 and Decem-
ber 2009. Cost-effectiveness data was extracted and converted into Canadian cur-
rency (CAD) to provide an estimate for Canadian public payers. The JODR and 
Ontario Public Drug Plan (OPDP) recommendations and decisions were analyzed in 
the context of these ICER values. RESULTS: Cost-effectiveness literature was found 
for 18 of the 24 drugs and of those, only 15 had published ICER values. ICER 
values ranged from approximately CAD$10,000/QALY to CAD$127,000/QALY. 
The average ICER of those cancer drugs considered to be cost-effective by the JODR 
was CAD$44,269/QALY, whereas the ICER for drugs considered not cost-effective 
was CAD$75,882/QALY (p = 0.10). Furthermore, drugs that were recommended 
for funding had a lower ICER when compared to those that were not recommended 
for funding ($57,578 vs. $81,490/QALY, p = 0.50). CONCLUSIONS: These ﬁndings 
suggest that while the ICER may be an important factor in the JODR decision-
making process, a careful examination of all factors leading to ﬁnal reimbursement 
decisions is needed to fully understand the relative importance of the ICER. Further 
research is required to determine if there are differences in the application of the 
ICER in decision-making processes for oncology medications versus other disease 
areas.
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COMPARITIVE KNOWLEDGE OF BREAST SELF EXAMINATION IN 
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BACKGROUND: Breast cancer is the most common type of cancer among women 
world wide ranking second in mortality from cancer. Bse is a screaning method that 
should be taught at an early age so as to educate women about the importance of 
early detection of breast cancer. OBJECTIVES: The aim of this study was to evaluate 
the level of knowledge of midwifery and nursing student regarding breast self –exami-
nation . METHODS: This study is descriptive on 23 midwifery and 69 nursing 
student.data collection tool was a questionnaire the included6 questions about demo-
graphic characteristics, and 14 question about knowledge breast self examination. 
Data analyzed by descriptive statistics. RESULTS: Our results show that the average 
age being (21–35),majo rity of them are single (%67/4)and (%29/3) twin. Our result 
showed no signiﬁcant differences in midwifery and nursing knowledge.(p > 5%). Our 
result showed the students of midwifery and nursing have mild knowledge. CONCLU-
SIONS: It seems that despite of the importance of the BSE in early diagnosis of breast 
cancer the majority of women have poor knowledge and practice about BSE.Based on 
the positive attitude of most women about BSE, it is that increasing the knowledge of 
women by education ways of breast cancer, especially BSE, this will be available by 
more attention of public health centers, TV and newspaper for increasing women 
awareness. Key word:breast,student,cancer,self examination.
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OBJECTIVES: Expert groups recommend men with local stage prostate cancer seek 
second opinions before choosing a management option. The nature of the physician-
patient interaction and outcomes for second versus primary opinion visits are 
unknown. METHODS: Newly diagnosed local stage prostate cancer patients and 
physicians at urology practices in three states participated in a survey of patient and 
doctor decision making following biopsy but prior to initiating treatment. Physicians 
were asked about the clinical status of the patient’s cancer, treatments discussed and 
recommended, and what factors most inﬂuenced the physician’s treatment 
recommendation(s). Patients were asked their treatment preference and what treat-
ments the physician recommended. RESULTS: A total of 238 local stage prostate 
cancer patients and their urologists completed surveys. Patient characteristics were: 
47% aged 60–69; 71% white, 16% black, 11% Hispanic; 49% had an income of 
≥$75,000. Ninety-ﬁve men were presenting for a primary consultation; 143 men were 
presenting for a second opinion. Among the initial consultation group, 64% were 
considering/planning a prostatectomy. Among the group seeking a second opinion, 
83% were considering/planning a prostatectomy. Of those seeking a primary recom-
mendation 59% had low risk disease, similar to the second opinion setting (54%). 
For low risk patients (primary vs. secondary opinions, respectively), physicians recom-
mended surgery for 80%/90%, external radiation for 38%/16%, seeds for 52%/14%, 
and watchful waiting for 25%/16%. In multivariate analysis, during an initial con-
sultation physicians recommended 0.51 more treatments (standard error 0.12, p < 
0.001) and were half as likely to consider the patient’s preference as a factor in their 
recommendations (OR 0.49, CI 026–0.95). CONCLUSIONS: Patient preferences and 
physician recommendations differ substantially in secondary versus primary opinion 
settings. In secondary opinion visits, patients are more likely to want prostatectomy 
and physicians are more likely to consider patient preference when making recom-
mendations. This is true even for men with low risk disease.
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OBJECTIVES: New treatments in oncology frequently imply in higher costs. Histori-
cally there is a lack of statistical data on cancer treatments in PHS in Brazil. Higher 
costs combined to lack of information may result in waste of resources. We present 
here real world data (RWD) on MM treatment collected from a dedicated database 
of cancer treatments Evidencias® (www.evidencias.com.br). METHODS: Between 
November of 2007 and October 2009 we retrieved all patients with MM registered 
on Evidencias®. Anthropometric data, staging, types of treatment, duration, and cost 
of chemotherapy and adjunctive therapies (AT) such as antiemetics, erythropoietin, 
colony stimulating factors and bisphosphonates were extracted. RESULTS: We identi-
ﬁed 98 patients (53% women and 47% men). The mean body surface area (BSA) 
was1.73 m2. Staging was stratiﬁed as follows: 21% Stage I, 8% stage II and 54% 
stage III. In 17% of the cases stage information was unavailable. Total cost of drugs 
was US$1,709,404.50. Chemotherapy drugs represented US$1,214,275.03 (71%) of 
which 98% (US$1,192,849.98) were due to the use of Bortezomib and 29% 
(US$495,129.46) to AT. Bortezomib was present in 57% of the treatments either 
isolated (42%) or combined to other chemotherapy (15%). Cyclophosphamide was 
used in 20% of the treatments, Doxorubicin in 18% and Melphalan in 5%. Mean 
duration of treatment was 3.9 cycles of chemotherapy. CONCLUSIONS: Real world 
data although a fundamental tool to guide health care providers in the correct alloca-
tion of resources, is still rare in Brazil e Latin America. Bortezomib is used in 57% of 
MM treatments but represents 98% of chemotherapy costs.
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OBJECTIVES: This study evaluated characteristics of postmenopausal women (PMW) 
who initiated raloxifene (RLX) therapy before and after the approval of the invasive 
breast cancer (BC) risk reduction (IBCRR) indications. METHODS: PMW 50 years 
and older with at least one claim for RLX in 2005–2008 and continuous enrollment 
over the study period (Jan 2004-Dec 2008) were identiﬁed in a large national com-
mercial and Medicare supplemental claims database. PMW on RLX were evaluated 
based on clinical and demographic variables such as age, provider specialty, fractures, 
bone mineral density (BMD) screening, Chronic Disease Score (CDS), family history 
of BC, and mammograms 12 months before and 12 months after the IBCRR indication 
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approval. RESULTS: PMW who initiated RLX following the IBCRR approval versus 
before approval were less likely to be in the 50–54 age group compared to all other 
age groups (Adjusted Odds Ratio [AOR] = 1.594 [age 55–59], 1.812 [age 60–64], 
1.667 [age 65–69], 1.782 [age 70+]). RLX initiators were more likely to have a lower 
CDS after the IBCRR approval vs. before approval (medium AOR = 0.795 [Conﬁdence 
Interval (CI): 0.711, 0.889], high AOR = 0.71 [CI: 0.626, 0.805]). After the IBCRR 
approval, RLX initiators had a greater likelihood of having a code for family history 
of BC in the claims database (AOR = 1.761 [CI: 1.213, 2.556]) compared to RLX 
initiators before approval. PMW who initiated RLX after IBCRR approval did not 
differ signiﬁcantly from those who initiated before approval with regard to mam-
mograms, fractures, BMD screening, and provider specialty. CONCLUSIONS: PMW 
who initiated RLX after the IBCRR approval were more likely to be older, have a 
lower CDS, and have a family history of BC compared with RLX initiators before 
approval. Factors such as mammograms, fractures, BMD screening, and provider 
specialty did not differ before and after the IBCRR approval.
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OBJECTIVES: The objective of this study was to evaluate the extent to which oncolo-
gist would participate and comply with a P4Q program employing clinical pathways. 
METHODS: A P4Q program was enacted in ﬁve northeastern states, USA, beginning 
August 1, 2008, and consisted of physician generated treatment (i.e. breast, lung, and 
colon-rectal cancer) and supportive care pathways (i.e. colony-stimulating factors, 
erythropoietin stimulating agents, and antiemetics). Practices were informed of the 
program three months in advance and allowed to sign up for the program prior to 
and during the ﬁrst year of the program. Feedback was provided to participants 
regarding compliance, and increased fee schedules in year 1 were adjusted in year 2 
contingent on compliance in year 1. Compliance was measured through the claims 
submitted by participating practices on cancer patients starting a new line of therapy 
after August 1, 2008. Compliance was deﬁned by provision of a drug or regimen not 
according to the deﬁned pathway. RESULTS: A total of 362 physicians were eligible 
for participation (174 community based; 34 hospital based; 154 academic based). 
49% of all physicians, 88% of community based, 44% of hospital based, and 6% of 
academic physicians signed up to participate in the program. 2,119 cancer patients 
were eligible for compliance analysis. Overall 85.9% of patients were judged compli-
ant to treatment pathways (90.5% breast, 90.9% colon, 72.3% lung). Overall 95.4% 
of patients were compliant to supportive care pathways (100% CSF, 98.6% ESAs, 
91.3% antiemetics). CONCLUSIONS: This study suggests high levels of compliance 
with clinical pathways may be achieved. Participation varied greatly by practice type. 
Additional analysis should consider evaluation of alternate deﬁnitions of compliance 
(e.g. errors of omission rather than commission) and reasons for non-participation 
(e.g. overlap of compliance with potential ﬁnancial advantage of participation).
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OBJECTIVES: Quality of care for cancer may improve with information technology 
products such as ELECTRONIC MEDICAL RECORDS (EMR). The objectives of this 
study were 1) to identify aspects of value of EMR use to providers in assessing and 
improving quality cancer care and 2) to identify issues in cost-effectiveness of EMR 
from the provider perspective. METHODS: A systematic literature review regarding 
perceptions of the quality of cancer care in the United States was conducted in 
PubMed, EMBASE, and Cochrane Reviews for the last 10 years, English only articles. 
Oncology medical subject heading (MESH) terms were cross-matched with quality of 
care MESH terms to obtain 875 abstracts. Of these, 140 publications were selected 
for full-article review based on deﬁned inclusion/exclusion criteria. RESULTS: Reports 
of EMR use among hospitals, hospital networks (for example, Veterans Hospital 
Administration), and moderately sized oncology practices indicated that providers 
rapidly obtained information on guideline adherence and determined whether patients 
received follow-up in physician ofﬁces. Cost savings were incurred across multidisci-
plinary teams because fewer tests were duplicated. Business management costs for 
billing were reduced. Other cost savings were lower labor costs due to reduced need 
for medical records staff, and staff to provide information among caregivers and to 
direct patient ﬂow. Cost effectiveness was variable for small physician practices, with 
some providers recovering the cost of the EMR system and others incurring serious 
ﬁnancial problems as a result of implementing EMR use in their practices. CONCLU-
SIONS: EMR may be ﬁnancially challenging for some small physician practices. 
However, it can assist providers in assessing whether their patients are receiving 
guideline-adherent care and aid in more efﬁcient processes of care, thereby improving 
overall quality of cancer care.
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OBJECTIVES: The oncology market has become one of the major focus areas for 
pharmaceutical and biotech ﬁrms. As of March 2009, 15,752 of 39,747 Phase I,II, 
and III trials listed on clinicaltrials.gov, were related to cancer (approximately 40%). 
This large interest in oncology stems from market success of cancer therapies launched 
in the past decade and the existence of high unmet need to treat different types of 
cancers. As the number of FDA approved cancer therapies increases there is a need 
to understand treatment patterns of these cancer drugs. METHODS: To understand 
the trends in usage and sales of cancer therapies we analyzed the US market (sales and 
prescription) 2005–2008 data for all FDA approved cancer drugs. Drugs were catego-
rized as targeted cancer therapies, chemotherapies, monoclonal antibodies, small 
molecules, branded and generics. RESULTS: During the past ﬁve years the usage of 
both targeted cancer therapies and chemotherapy drugs has increased by high double 
digit rates. From 2005–2008, the total prescriptions for targeted cancer therapies and 
chemotherapies increased by 66% and 30%, respectively. While the sales of both types 
of these drugs are expanding, the majority of sales growth is attributed to an increasing 
uptake of targeted cancer drugs. The sales share of targeted cancer therapies in the 
US oncology market increased from 36% in 2004 to 56% in 2008. Among targeted 
cancer therapies, majority (more than 75%) of uptake belongs to monoclonal antibod-
ies. CONCLUSIONS: The usage and sales trends show a signiﬁcant increase in the 
use of cancer drugs. The high usage of targeted cancer therapies versus chemotherapies 
shows the rapidly changing nature of cancer treatment regimen.
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OBJECTIVES: Systemic chemotherapy is a vital component of breast cancer manage-
ment but early-onset toxicities like neutropenia hinder its administration. Primary 
prophylactic (PP) use of granulocyte-colony stimulating factors (G-CSF) helps prevent 
neutropenia and ensures successful chemotherapy completion. Nevertheless, lack of 
speciﬁc guidelines for G-CSF administration in the elderly has lead to unexplained 
geographic and racial, and counter-intuitive clinical variations. For example, older 
individuals with higher co-morbidities (at higher neutropenia risk) have lower prob-
ability of G-CSF receipt. This study examined the reasons for these variations and for 
the ﬁrst time looked at variations in PP administration in breast cancer patients. 
METHODS: A retrospective observational study of newly diagnosed breast cancer 
patients receiving chemotherapy was performed using the 1994–2003 SEER-Medicare 
data. Univariate analyses and multi-variate logistic regressions were used to explore 
the determinants of PPG-CSF administration. Previously unexplored clinical and 
therapeutic characteristics (e.g. chemotherapy characteristics before the administration 
of PPG-CSF) were also included. RESULTS: Univariate analyses demonstrated geo-
graphic, racial and clinical disparities similar to previous studies. However, multi-
variate analyses revealed that controlling for chemotherapy characteristics (type and 
number of drugs and between cycle duration) made the correlation of age and other 
clinical characteristics with PPG-CSF administration insigniﬁcant. Signiﬁcant geo-
graphic and racial disparities existed. Exploration of geographic variations suggested 
that regions with higher rates of PPG-CSF administration have higher proportion of 
physicians administering them; none of the physicians using PPG-CSF administered it 
on a signiﬁcantly higher proportion of their patients. CONCLUSIONS: Physicians’ 
decision to administer PPG-CSF is predominantly driven by neutropenia risk associ-
ated with pre-planned chemotherapy regimen. Older, sicker women at a higher risk 
of neutropenia received less intense/toxic chemotherapy thus did not require PPG-CSF. 
Geographic variations are driven by provider-level variations in PPG-CSF administra-
tion with no evidence for overuse among the providers. Racial and geographic dispari-
ties have no clinical basis and are a matter of concern.
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OBJECTIVES: To examine the prescribing patterns of the recommended pharmaco-
logic treatments for metastatic renal cell carcinoma (mRCC). METHODS: A retrospec-
tive claims-based analysis was conducted that identiﬁed incident mRCC patients 
(18–64 years) in the Thomson Reuters MarketScan Commercial Claims Database 
(January 2005–September 2008). Patients were required to have at least 6 months of 
continuous enrollment before the index date (ﬁrst metastases claim) and at least 30 days 
of continuous enrollment after the index date. Treatment patterns were described as 
proportions of mRCC patients receiving the following guideline-recommended phar-
macologic agents: immunotherapies (interferon-alpha and interleukin-2) and the newer 
targeted agents (sunitinib, sorafenib, bevacizumab, temsirolimus and everolimus), 
either as initial or second-line therapies any time on or after the index date. RESULTS: 
A total of 1390 patients with mRCC were included in the analysis. Mean age was 55.6 
years and 70.5% were male. The mean continuous enrollment after diagnosis of metas-
